AveXis Inc (AVXS) Insider Brian K. Kaspar Sells 15,000 Shares
AveXis Inc (NASDAQ:AVXS) insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction on Thursday, March 1st. The shares were sold at an average price of $126.15, for a total value of $1,892,250.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of AveXis Inc (NASDAQ AVXS) traded up $0.19 on Monday, reaching $130.38. The company had a trading volume of 520,968 shares, compared to its average volume of 577,988. The stock has a market cap of $4,600.00 and a PE ratio of -18.08. AveXis Inc has a twelve month low of $65.23 and a twelve month high of $132.66.
AveXis (NASDAQ:AVXS) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($2.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.91). equities analysts forecast that AveXis Inc will post -7.53 EPS for the current year.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Xact Kapitalforvaltning AB purchased a new stake in AveXis during the 4th quarter worth about $316,000. Alkeon Capital Management LLC purchased a new stake in AveXis during the 4th quarter worth about $553,000. Element Capital Management LLC purchased a new stake in AveXis during the 4th quarter worth about $7,274,000. TIAA CREF Investment Management LLC lifted its holdings in AveXis by 10.3% during the 4th quarter. TIAA CREF Investment Management LLC now owns 69,078 shares of the company’s stock worth $7,645,000 after purchasing an additional 6,437 shares in the last quarter. Finally, Teachers Advisors LLC lifted its holdings in AveXis by 1.5% during the 4th quarter. Teachers Advisors LLC now owns 89,226 shares of the company’s stock worth $9,875,000 after purchasing an additional 1,277 shares in the last quarter. 81.99% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “AveXis Inc (AVXS) Insider Brian K. Kaspar Sells 15,000 Shares” was first published by Daily Political and is owned by of Daily Political. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2018/03/05/avexis-inc-avxs-insider-brian-k-kaspar-sells-15000-shares.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.